<DOC>
	<DOCNO>NCT02603445</DOCNO>
	<brief_summary>This phase Ib multi-center , open-label study : escalation part follow expansion part . The primary purpose Phase Ib CBCL201X2102C study characterize safety tolerability BCL201 combine idelalisib patient FL MCL . Approximately 65 patient enrol . The primary endpoint Phase Ib frequency , severity seriousness AEs , lab abnormality safety parameter ECG change . An adaptive Bayesian logistic regression model ( BLRM ) guide dose escalation determine MTD/RDE phase Ib . In addition Bayesian regression model use estimate dose-exposure relationship BCL201 idelalisib order guide escalation step . A Bayesian method expansion part use primary activity objective . The study data analyze report base patient ' data escalation expansion part .</brief_summary>
	<brief_title>Study Safety Efficacy BCL201 Idelalisib Patients With FL MCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Histologically confirm diagnosis FL MCL accord WHO 2008 Relapsed refractory least one ( FL ) two ( MCL ) , four , prior line antineoplastic regimen . Either FDGavid FDGPET measurable disease CT cross sectional imaging : &gt; 1.5 cm nodal lesion , &gt; 1.0 cm extra nodal lesion . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 For dose escalation part : Patients MCL high risk tumor lysis syndrome Prior treatment PI3Kδ Bcl2 inhibitor . Any malignant disease History serious allergic reaction include anaphylaxis toxic epidermal necrolysis Inadequate organ function Concomitant treatment : Strong CYP3A4/5 inducer inhibitor Sensitive CYP3A4/5 substrates CYP3A4/5 substrate narrow therapeutic index ( NTI ) Sensitive CYP2D6 substrates CYP2D6 substrates NTI Selected dual substrate CYP3A4/5 CYP2C8 Selected dual substrate CYP3A4/5 CYP2D6 Selected dual substrate OATP CYP450 QT prolong drug know risk induce TdP Proton pump inhibitor Treatment warfarin equivalent vitamin K antagonist . Other investigational therapy Herbal preparations/ medication Grapefruit , Seville oranges product contain either juice Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>BCL201</keyword>
	<keyword>idelalisib</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>FL</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>MCL</keyword>
</DOC>